Debt-to-equity of Trevi Therapeutics, Inc. from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Trevi Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 30 Sep 2025.
  • Trevi Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 7%, a 41% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Trevi Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 7% -4% -41% 30 Sep 2025
Q2 2025 8% 0% -2.8% 30 Jun 2025
Q1 2025 11% +4% +51% 31 Mar 2025
Q4 2024 12% +3% +30% 31 Dec 2024
Q3 2024 11% 0% +2.1% 30 Sep 2024
Q2 2024 9% -4% -34% 30 Jun 2024
Q1 2024 7% -11% -59% 31 Mar 2024
Q4 2023 9% -17% -65% 31 Dec 2023
Q3 2023 11% -30% -74% 30 Sep 2023
Q2 2023 13% -70% -84% 30 Jun 2023
Q1 2023 18% -128% -88% 31 Mar 2023
Q4 2022 26% -92% -78% 31 Dec 2022
Q3 2022 41% -60% -60% 30 Sep 2022
Q2 2022 83% 30 Jun 2022
Q1 2022 146% 31 Mar 2022
Q4 2021 118% 31 Dec 2021
Q3 2021 101% 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.